Clinical-pathological correlation of K-Ras mutation and ERK phosphorylation in colorectal cancer

Cheng Jeng Tai, Chun Chao Chang, Ming Chung Jiang, Chung Min Yeh, Tzu Cheng Su, Pei Ru Wu, Chih Jung Chen, Kun Tu Yeh, Shu Hui Lin, Hung Chang Chen

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The Ras-ERK pathway is frequently up-regulated in colorectal cancer.We analyzed the clinical-pathological correlation of K-Ras mutation and phospho-ERK expression in colorectal cancer. K-Ras mutations were detected in only 32.5% (41/126) of the colorectal cancer cases, while all cancers were positive for phospho-ERK staining. Colorectal cancer with wild-type K-Ras and low phospho-ERK expression had a significantly higher survival rate (log-rank P=0.04). There were 9 cases of K-Ras mutation/low phospho-ERK diseases; 88.9%(8/9) of them were stage III/IV diseases. High phospho-ERK expression was associated with a high stage and T status of the cancer, yet combined K-Ras mutation/phospho-ERK expression analysis further increased the efficiency of colorectal cancer prognosis. Our results demonstrate that Ras-ERK pathway correlated closely with colorectal cancer progression. Moreover, although colorectal cancer with K-Ras mutations has a more aggressive phenotype; the mutation rate is not very high. Phospho-ERK may be a useful marker in combination with K-Ras for improving the prognosis of colorectal cancer.

Original languageEnglish
Pages (from-to)93-100
Number of pages8
JournalPolish Journal of Pathology
Volume63
Issue number2
Publication statusPublished - 2012

Fingerprint

Colorectal Neoplasms
Phosphorylation
Mutation
MAP Kinase Signaling System
Mutation Rate
Neoplasms
Staining and Labeling
Phenotype

Keywords

  • Colorectal cancer
  • ERK
  • Mutation
  • Phosphorylation
  • Ras

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Clinical-pathological correlation of K-Ras mutation and ERK phosphorylation in colorectal cancer. / Tai, Cheng Jeng; Chang, Chun Chao; Jiang, Ming Chung; Yeh, Chung Min; Su, Tzu Cheng; Wu, Pei Ru; Chen, Chih Jung; Yeh, Kun Tu; Lin, Shu Hui; Chen, Hung Chang.

In: Polish Journal of Pathology, Vol. 63, No. 2, 2012, p. 93-100.

Research output: Contribution to journalArticle

Tai, CJ, Chang, CC, Jiang, MC, Yeh, CM, Su, TC, Wu, PR, Chen, CJ, Yeh, KT, Lin, SH & Chen, HC 2012, 'Clinical-pathological correlation of K-Ras mutation and ERK phosphorylation in colorectal cancer', Polish Journal of Pathology, vol. 63, no. 2, pp. 93-100.
Tai, Cheng Jeng ; Chang, Chun Chao ; Jiang, Ming Chung ; Yeh, Chung Min ; Su, Tzu Cheng ; Wu, Pei Ru ; Chen, Chih Jung ; Yeh, Kun Tu ; Lin, Shu Hui ; Chen, Hung Chang. / Clinical-pathological correlation of K-Ras mutation and ERK phosphorylation in colorectal cancer. In: Polish Journal of Pathology. 2012 ; Vol. 63, No. 2. pp. 93-100.
@article{65be4b2e05514e4a8da7bc404c8c3878,
title = "Clinical-pathological correlation of K-Ras mutation and ERK phosphorylation in colorectal cancer",
abstract = "The Ras-ERK pathway is frequently up-regulated in colorectal cancer.We analyzed the clinical-pathological correlation of K-Ras mutation and phospho-ERK expression in colorectal cancer. K-Ras mutations were detected in only 32.5{\%} (41/126) of the colorectal cancer cases, while all cancers were positive for phospho-ERK staining. Colorectal cancer with wild-type K-Ras and low phospho-ERK expression had a significantly higher survival rate (log-rank P=0.04). There were 9 cases of K-Ras mutation/low phospho-ERK diseases; 88.9{\%}(8/9) of them were stage III/IV diseases. High phospho-ERK expression was associated with a high stage and T status of the cancer, yet combined K-Ras mutation/phospho-ERK expression analysis further increased the efficiency of colorectal cancer prognosis. Our results demonstrate that Ras-ERK pathway correlated closely with colorectal cancer progression. Moreover, although colorectal cancer with K-Ras mutations has a more aggressive phenotype; the mutation rate is not very high. Phospho-ERK may be a useful marker in combination with K-Ras for improving the prognosis of colorectal cancer.",
keywords = "Colorectal cancer, ERK, Mutation, Phosphorylation, Ras",
author = "Tai, {Cheng Jeng} and Chang, {Chun Chao} and Jiang, {Ming Chung} and Yeh, {Chung Min} and Su, {Tzu Cheng} and Wu, {Pei Ru} and Chen, {Chih Jung} and Yeh, {Kun Tu} and Lin, {Shu Hui} and Chen, {Hung Chang}",
year = "2012",
language = "English",
volume = "63",
pages = "93--100",
journal = "Polish Journal of Pathology",
issn = "1233-9687",
publisher = "Versalius University Medical Publisher",
number = "2",

}

TY - JOUR

T1 - Clinical-pathological correlation of K-Ras mutation and ERK phosphorylation in colorectal cancer

AU - Tai, Cheng Jeng

AU - Chang, Chun Chao

AU - Jiang, Ming Chung

AU - Yeh, Chung Min

AU - Su, Tzu Cheng

AU - Wu, Pei Ru

AU - Chen, Chih Jung

AU - Yeh, Kun Tu

AU - Lin, Shu Hui

AU - Chen, Hung Chang

PY - 2012

Y1 - 2012

N2 - The Ras-ERK pathway is frequently up-regulated in colorectal cancer.We analyzed the clinical-pathological correlation of K-Ras mutation and phospho-ERK expression in colorectal cancer. K-Ras mutations were detected in only 32.5% (41/126) of the colorectal cancer cases, while all cancers were positive for phospho-ERK staining. Colorectal cancer with wild-type K-Ras and low phospho-ERK expression had a significantly higher survival rate (log-rank P=0.04). There were 9 cases of K-Ras mutation/low phospho-ERK diseases; 88.9%(8/9) of them were stage III/IV diseases. High phospho-ERK expression was associated with a high stage and T status of the cancer, yet combined K-Ras mutation/phospho-ERK expression analysis further increased the efficiency of colorectal cancer prognosis. Our results demonstrate that Ras-ERK pathway correlated closely with colorectal cancer progression. Moreover, although colorectal cancer with K-Ras mutations has a more aggressive phenotype; the mutation rate is not very high. Phospho-ERK may be a useful marker in combination with K-Ras for improving the prognosis of colorectal cancer.

AB - The Ras-ERK pathway is frequently up-regulated in colorectal cancer.We analyzed the clinical-pathological correlation of K-Ras mutation and phospho-ERK expression in colorectal cancer. K-Ras mutations were detected in only 32.5% (41/126) of the colorectal cancer cases, while all cancers were positive for phospho-ERK staining. Colorectal cancer with wild-type K-Ras and low phospho-ERK expression had a significantly higher survival rate (log-rank P=0.04). There were 9 cases of K-Ras mutation/low phospho-ERK diseases; 88.9%(8/9) of them were stage III/IV diseases. High phospho-ERK expression was associated with a high stage and T status of the cancer, yet combined K-Ras mutation/phospho-ERK expression analysis further increased the efficiency of colorectal cancer prognosis. Our results demonstrate that Ras-ERK pathway correlated closely with colorectal cancer progression. Moreover, although colorectal cancer with K-Ras mutations has a more aggressive phenotype; the mutation rate is not very high. Phospho-ERK may be a useful marker in combination with K-Ras for improving the prognosis of colorectal cancer.

KW - Colorectal cancer

KW - ERK

KW - Mutation

KW - Phosphorylation

KW - Ras

UR - http://www.scopus.com/inward/record.url?scp=84864842724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864842724&partnerID=8YFLogxK

M3 - Article

C2 - 22864777

AN - SCOPUS:84864842724

VL - 63

SP - 93

EP - 100

JO - Polish Journal of Pathology

JF - Polish Journal of Pathology

SN - 1233-9687

IS - 2

ER -